endocrine:glp1:semaglutide
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
| endocrine:glp1:semaglutide [2026/02/13 00:16] – [Adverse Effects] andrew2393cns | endocrine:glp1:semaglutide [2026/02/13 00:17] (current) – [Clinical Pearls] andrew2393cns | ||
|---|---|---|---|
| Line 118: | Line 118: | ||
| ===== Contraindications ===== | ===== Contraindications ===== | ||
| - | • Personal or family history of medullary thyroid carcinoma | + | * • Personal or family history of medullary thyroid carcinoma |
| - | • MEN2 syndrome | + | |
| - | • Severe GI disease | + | |
| Use caution in: | Use caution in: | ||
| - | • History of pancreatitis | + | * • History of pancreatitis |
| -------------------------------------------------------------------- | -------------------------------------------------------------------- | ||
| Line 131: | Line 131: | ||
| [[endocrine: | [[endocrine: | ||
| - | • Shorter acting | + | * • Shorter acting |
| - | • Less weight loss | + | |
| [[endocrine: | [[endocrine: | ||
| - | • Daily injection | + | * • Daily injection |
| - | • Proven ASCVD benefit | + | |
| [[endocrine: | [[endocrine: | ||
| - | • Weekly injection | + | * • Weekly injection |
| - | • Strong ASCVD benefit | + | |
| Semaglutide: | Semaglutide: | ||
| - | • Strongest weight loss among GLP-1 RAs | + | * • Strongest weight loss among GLP-1 RAs |
| - | • Strong ASCVD reduction | + | |
| - | • Available oral formulation | + | |
| -------------------------------------------------------------------- | -------------------------------------------------------------------- | ||
| Line 153: | Line 153: | ||
| Semaglutide: | Semaglutide: | ||
| - | • Strong ASCVD reduction | + | * • Strong ASCVD reduction |
| - | • Weight loss dominant | + | |
| [[endocrine: | [[endocrine: | ||
| - | • Strong heart failure benefit | + | * • Strong heart failure benefit |
| - | • Strong renal protection | + | |
| These classes are often combined in cardiometabolic patients. | These classes are often combined in cardiometabolic patients. | ||
| Line 167: | Line 167: | ||
| ===== Clinical Pearls ===== | ===== Clinical Pearls ===== | ||
| - | ✔ Weekly or oral option | + | * ✔ Weekly or oral option |
| - | ✔ Powerful weight loss | + | |
| - | ✔ Reduces ASCVD events | + | |
| - | ✔ Low hypoglycemia risk | + | |
| - | ✔ Not a core heart failure therapy | + | |
| - | ✔ Monitor for GI intolerance | + | |
| -------------------------------------------------------------------- | -------------------------------------------------------------------- | ||
endocrine/glp1/semaglutide.1770941777.txt.gz · Last modified: by andrew2393cns
